Infectious complications
| . | No abatacept (n = 14) . | Abatacept (n = 50) . | P value . |
|---|---|---|---|
| BSI, n (%) | 5 (35) | 7 (14) | .1 |
| Organisms: | Organisms: | ||
| Bacteroides sp | E coli | ||
| Escherichia coli | Moraxella lacunata | ||
| Klebsiella sp (n = 2) | Streptococcus pyogenes | ||
| Staphylococcus epidermidis | Streptococcus agalactiae | ||
| Streptococcus mitis (n = 2) | |||
| Serratia marcescens | |||
| Viral disease, n (%) | 3 (21) | 7 (14) | .6 |
| CMV pneumonitis (n = 1) | CMV pneumonitis (n = 1) | ||
| BK virus hemorrhagic cystitis (n = 1) | BK virus hemorrhagic cystitis (n = 6) | ||
| Disseminated adenovirus (n = 1) | |||
| Viral reactivation, n (%) | |||
| EBV | 7 (50) | 25 (50) | 1.0 |
| BK | 4 (28) | 7 (14) | .2 |
| CMV | 7 (50) | 28 (56) | .7 |
| Adenovirus | 2 (14) | 1 (2) | .1 |
| Any (≥1) viral reactivation | 10 (71) | 40 (80) | .4 |
| . | No abatacept (n = 14) . | Abatacept (n = 50) . | P value . |
|---|---|---|---|
| BSI, n (%) | 5 (35) | 7 (14) | .1 |
| Organisms: | Organisms: | ||
| Bacteroides sp | E coli | ||
| Escherichia coli | Moraxella lacunata | ||
| Klebsiella sp (n = 2) | Streptococcus pyogenes | ||
| Staphylococcus epidermidis | Streptococcus agalactiae | ||
| Streptococcus mitis (n = 2) | |||
| Serratia marcescens | |||
| Viral disease, n (%) | 3 (21) | 7 (14) | .6 |
| CMV pneumonitis (n = 1) | CMV pneumonitis (n = 1) | ||
| BK virus hemorrhagic cystitis (n = 1) | BK virus hemorrhagic cystitis (n = 6) | ||
| Disseminated adenovirus (n = 1) | |||
| Viral reactivation, n (%) | |||
| EBV | 7 (50) | 25 (50) | 1.0 |
| BK | 4 (28) | 7 (14) | .2 |
| CMV | 7 (50) | 28 (56) | .7 |
| Adenovirus | 2 (14) | 1 (2) | .1 |
| Any (≥1) viral reactivation | 10 (71) | 40 (80) | .4 |
EBV, Epstein-Barr virus.